Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.42 |
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777791 | 0.81 | NPC1 (0.47) | NPC1RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL1886305 | 0.79 | NPC1 (0.52) | NPC1RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL12417689 | 0.76 | NPC1 (0.37) | NPC1RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL1895519 | 0.74 | LMNA (0.51) | NPC1RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL12417654 | 0.73 | TSHR (0.39) | NPC1RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL1780290 | 0.72 | NPC1 (0.44) | NPC1RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL1883150 | 0.71 | ALDH1A1 (0.48) | RAB9AALDH1A1KDM4ELMNATP53 | |
| SCHEMBL1887668 | 0.70 | HTT (0.57) | NPC1RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL12507634 | 0.69 | NPC1 (0.46) | NPC1RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL12673302 | 0.69 | NPC1 (0.33) | NPC1RAB9AALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887002-B1 | CARBOXAMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8304437-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | ARIMORI SADAYUKI | 2011-07-14 | — | — | US | disclosed |
| US-7935716-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090076063-A1 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1887002-A1 | CARBOXAMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076063-A1 | Carboxamide compound and use of the same | CBR3, SIRT2, SIRT1 | NPC1 1710/4885RAB9A 1024/4885ALDH1A1 3016/4885 |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | CBR3, SIRT2, SIRT1 | NPC1 1710/4885RAB9A 1024/4885ALDH1A1 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.